Grants and Contributions:

Back to search

Title:

The development of supplemental products to Kane's revyve Antimicrobial Wound Gel for the wound care market.

Agreement Number:

1021203

Agreement Value:

$200,000.00

Agreement Date:

Aug 1, 2024 - Mar 31, 2026

Description:

The Design and Development of products based on the revyve Antimicrobial Wound Gel. The sterile wound gel, primarily intended to be used in surgical rooms for post surgery infection prevention; the spray wound gel, primarily intended to be used for large surface burn wounds to clear any existing infection and protect from subsequent infection. Application and removal wound be contactless for these sensitive wounds; and the wound cleanser that is intended to be used prior to debridement and treatment with the revyve wound gel as part of a wound management regimen. The project involves all stages of development for all products, from conception to design transfer.

Organization:

National Research Council Canada

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:

Winnipeg, Manitoba, CA R3T 6G2

Reference Number:

172-2024-2025-Q2-1021203

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

884326117

Recipient Type:

For-profit organization

Recipient's Legal Name:

Kane Biotech Inc.

Federal Riding Name:

Winnipeg South

Federal Riding Number:

46013

Program:

Industrial Research Assistance Program – Contributions to Firms

Program Purpose:

Coverage:

IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.

NAICS Code:

325410